ArticlePloS one2026
ABO and RhD blood group antigen frequencies in patients and blood donors: Implications for the U.S. blood supply.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundABO/Rh blood groups play a pivotal role in the practice of transfusion medicine. To our knowledge, there have been no large studies reporting these blood group antigen frequencies in the United States (US) since 2004, and the most recent large study only reported antigen frequencies for donors, not patients. We sought to determine and compare the ABO/RhD antigen frequencies in patient and donor populations.
methodsIn this multi-center retrospective cohort study, five California academic medical centers and one national blood center reviewed blood group and demographic data from patients, California blood donors, and US blood donors who underwent ABO/RhD typing during a 5-year period. Data were analyzed to characterize each population and to compare the patient and donor populations.
resultsABO/RhD typing for 467,748 patients, 719,211 California blood donors, and 7,449,831 US blood donors were included in this study. Among patients, California donors, and US donors, group O was represented by 46.2%, 50.8%, and 48.8% of the population, respectively; group A 35.8%, 32.1%, and 36.0%; group B 14.1%, 13.0%, and 11.3%; and group AB 3.9%, 4.1%, and 3.9%. Among patients, California donors, and US donors, RhD-positive individuals represented 90.0%, 88.4%, and 83.0% of the population. Patient ABO/RhD frequencies varied significantly by site, age, and sex, and differed from the ABO/RhD frequencies of California and US donors.
conclusionsThis study reports ABO/RhD frequencies in a large cohort of California patients, California blood donors, and US blood donors, which may inform donor recruitment, inventory management, and policy development. Patient and donor ABO/RhD frequencies differ significantly, indicating potential misalignment that may be consequential and warrants investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.